Latest Posts

The Most Common Misunderstanding about Compulsory Licensing

The belief that a country can only use compulsory licensing in cases of public health emergencies is a myth that has proven difficult to...

The Italian Exception – A personalised approach to accessing high-priced patented medicines

At the end of March 2017, the Italian Minister of Health Beatrice Lorenzin has authorised the importation of generic medicines. She did this with...

Access to medicines amendment of the WTO TRIPS Agreement. Hype or hope?

On 30 January 2017 the World Trade Organization (WTO) announced the first ever amendment to the TRIPS Agreement under the headline WTO members welcome...

UN High-Level Panel on Access to Medicines calls for stronger public leadership in innovation...

The UN High-Level Panel on Access to Medicines published its report on 14 September. The Panel was established on 19 November 2015 by UN...

High medicines prices in Europe – do not Brexit the people

The issues of high priced medicines and problems with access to medicines have for many years been themes belonging to the realm of global...

Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...

Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...